We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+13.47%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.57B
AUM Growth
+$553M
Cap. Flow
+$561M
Cap. Flow %
15.73%
Top 10 Hldgs %
49.57%
Holding
170
New
38
Increased
32
Reduced
29
Closed
33

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$104M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$79.7M
3
ASND icon
Ascendis Pharma A/S
ASND
+$55.2M
4
YARW
Yarrow Bioscience
YARW
+$54M
5
FOLD
Amicus Therapeutics
FOLD
+$32.5M

Top Sells

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$58.5M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$32.9M
3
ISRG icon
Intuitive Surgical
ISRG
+$25.4M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$24.2M
5
ZBH icon
Zimmer Biomet
ZBH
+$24.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.46%
2 Consumer Staples 0.67%
3 Consumer Discretionary 0.06%
4 Industrials 0.02%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZLAB icon
151
Zai Lab
ZLAB
$2.94B
– –
-175,000
Closed -$3.71M
LUMO
152
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-50,000
Closed -$3.65M
DCPH
153
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-102,500
Closed -$2.32M
ARAV
154
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-248,027
Closed -$3.27M
ACER
155
DELISTED
Acer Therapeutics Inc
ACER
– –
-150,000
Closed -$2.09M
SPPI
156
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-32,154
Closed -$609K
ATRS
157
DELISTED
Antares Pharma, Inc.
ATRS
– –
-3,745,662
Closed -$7.45M
ZSAN
158
DELISTED
Zosano Pharma Corporation
ZSAN
– –
-714
Closed -$260K
VCRA
159
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
– –
-35,169
Closed -$1.06M
NEOS
160
DELISTED
Neos Therapeutics, Inc
NEOS
– –
-300,000
Closed -$3.06M
OXFD
161
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
– –
-500,356
Closed -$6.99M
PFNX
162
DELISTED
Pfenex Inc.
PFNX
– –
-519,773
Closed -$1.38M
TSRO
163
DELISTED
TESARO, Inc.
TSRO
– –
-129,372
Closed -$10.7M
KERX
164
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-83,386
Closed -$388K
JUNO
165
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-300,000
Closed -$93K
SCMP
166
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
– –
-40,062
Closed -$719K
RXDX
167
DELISTED
Ignyta, Inc.
RXDX
– –
-30,211
Closed -$807K
3 4 5 6
7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q1 2018 Portfolio in Review

As of Q1 2018, Perceptive Advisors held 170 positions worth $3.57B, up 18% from $3.02B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors deployed $561M of net new capital in Q1 2018, opening 38 new positions and adding to 32 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was AnaptysBio, an estimated $58.5M trimmed.

  • Perceptive Advisors's largest Q1 2018 buy was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.
  • Perceptive Advisors added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018, an estimated $79.7M increase.
  • Perceptive Advisors's biggest Q1 2018 reduction was AnaptysBio, cutting an estimated $58.5M.
  • Perceptive Advisors fully exited Zimmer Biomet in Q1 2018, selling an estimated $24.1M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $3.57B portfolio in Q1 2018.
  • Perceptive Advisors opened 38 new positions and closed 33 in Q1 2018.
  • Perceptive Advisors's portfolio value rose 18% quarter-over-quarter to $3.57B.

Based on Perceptive Advisors's 13F filing for Q1 2018, filed 15 May 2018.